All
Duo Falls Short in Treating Advanced Kidney Cancer
June 14th 2017Progression-free survival (PFS) was not significantly improved with the combination of dalantercept plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to the results from the phase 2 DART trial.
Expert Discusses Advances in Treating CLL
June 13th 2017Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).
Drug Pair is Active in Melanoma and Head and Neck Cancer
June 7th 2017Patients with squamous cell carcinoma of the head and neck (SCCHC) and those with melanoma saw some promising activity with the drug combination of epacadostat and Opdivo (nivolumab), according to findings from the phase 1/2 ECHO-204 study presented at the 2017 ASCO Annual Meeting.